Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

BACKGROUND: Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. OBJECTIVE: To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT random...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur Urol
Egile Nagusiak: Johnston, Thomas J., Shaw, Greg L., Lamb, Alastair D., Parashar, Deepak, Greenberg, David, Xiong, Tengbin, Edwards, Alison L., Gnanapragasam, Vincent, Holding, Peter, Herbert, Phillipa, Davis, Michael, Mizielinsk, Elizabeth, Lane, J. Athene, Oxley, Jon, Robinson, Mary, Mason, Malcolm, Staffurth, John, Bollina, Prasad, Catto, James, Doble, Andrew, Doherty, Alan, Gillatt, David, Kockelbergh, Roger, Kynaston, Howard, Prescott, Steve, Paul, Alan, Powell, Philip, Rosario, Derek, Rowe, Edward, Donovan, Jenny L., Hamdy, Freddie C., Neal, David E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier Science 2017
Gaiak:
Platinum Priority – Prostate Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5289293/
https://ncbi.nlm.nih.gov/pubmed/27720537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.09.040
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak